Product Images Simvastatin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Simvastatin NDC 51655-113 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 51655 113 26 Rev A 02 23
NDC 51655-113-26 Rev. A 0223 Simvastatin Tablets, USP 40 mg, 90 Tablets. This medication is prescription only and should be stored in its original container. Dosage information can be found in the package insert. Children should not have access to this medication. The medication is manufactured by Biocon Pharma Inc. and repackaged by Northwind Pharmaceuticals. The tablets contain 40mg of Simvastatin USP. The lot number is 0000000000, and the medication has an expiration date of 00/00/0000.*
Footnote for Table 3 - Footnote for Table 3
This text provides information on the potential inhibitors of CYP3Ad, including ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone. It also mentions simvastatin acid, the effect of grapefruit juice on simvastatin pharmacokinetics, and the dosing regimen for grapefruit juice and simvastatin. This information may be useful for healthcare professionals treating patients with simvastatin or other medications metabolized by CYP3Ad.*
Figure 9 - simvastatin 10
table2 - simvastatin 2
The table shows the adverse reactions reported by patients treated with Simvastatin when compared to Placebo. The adverse reactions are categorized into different body systems like cardiovascular, digestive, musculoskeletal, etc. Some of the reactions that were reported in a higher percentage of patients treated with Simvastatin when compared to Placebo were abdominal pain, atrial fibrillation, constipation, diabetes mellitus, myalgia, insomnia, and eczema.*
Structure - simvastatin 3
table 3 - simvastatin 4
table 4 - simvastatin 5
Figure 5 - simvastatin 6
This appears to be a medical study report presenting the characteristics and risk ratios of patients with or without certain cardiovascular conditions who were administered different treatments. The text contains tables with numbered characteristics and their corresponding values. The study is likely investigating the efficacy of Simvastatin and/or Placebo in preventing major vascular and/or coronary events.*
Figure 6 - simvastatin 7
Figure 7 - simvastatin 8
Figure 8 - simvastatin 9
table 1 - table1
This text provides a table of drug interactions that are associated with an increased risk of myopathy and rhabdomyolysis. The interacting agents listed in the table include strong CYP3A4 inhibitors, HIV protease inhibitors, verapamil, diltiazem, amiodarone, and others. Prescribing recommendations are provided based on the interactions listed. The text also warns against exceeding certain dosages of simvastatin in patients taking certain medications and advises against consuming grapefruit juice.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.